Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$81.11

0.11 (0.14%)

, MRK

Merck

$62.46

-0.06 (-0.10%)

08:09
10/05/16
10/05
08:09
10/05/16
08:09

Eli Lilly to present on its clinical cancer portfolio at ESMO Congress

Eli Lilly (LLY) will present data from several studies of its clinical cancer portfolio during the European Society of Medical Oncology's 2016 Congress. Presentations include new data on abemaciclib, a CDK 4 and CDK 6 inhibitor, and olaratumab, a PDGFRalpha blocking antibody that recently received a positive CHMP opinion, as well as data on: pemetrexed, a multi-targeted antifolate; ramucirumab, a VEGF Receptor 2 antagonist; necitumumab, an EGFR blocking antibody; and prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor. The presentations on pemetrexed, ramucirumab and necitumumab include data from a few of Lilly's immuno-oncology clinical collaborations with Merck (MRK) in trials that are evaluating these molecules in combination with Merck's pembrolizumab. The first results from KEYNOTE-021G - which studied pembrolizumab in combination with pemetrexed-plus-carboplatin compared to pemetrexed-plus-carboplatin alone for the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer regardless of PD-L1 expression - will be featured in the Presidential Symposium on October 9.

LLY

Eli Lilly

$81.11

0.11 (0.14%)

MRK

Merck

$62.46

-0.06 (-0.10%)

  • 07

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

LLY Eli Lilly
$81.11

0.11 (0.14%)

09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
MRK Merck
$62.46

-0.06 (-0.10%)

08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.

TODAY'S FREE FLY STORIES

FND

Floor & Decor Holdings

20:03
04/26/17
04/26
20:03
04/26/17
20:03
Syndicate
Floor & Decor Holdings 8.824M share IPO priced at $21.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

SNE

Sony

$33.58

-0.07 (-0.21%)

, FOX

21st Century Fox

$30.05

0.16 (0.54%)

20:02
04/26/17
04/26
20:02
04/26/17
20:02
Periodicals
Sony narrows search for studio boss to Vinciquerra, WSJ says »

Former Fox (FOX) TV head…

SNE

Sony

$33.58

-0.07 (-0.21%)

FOX

21st Century Fox

$30.05

0.16 (0.54%)

FOXA

21st Century Fox

$30.74

0.13 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 10

    May

  • 24

    May

  • 25

    May

  • 15

    Jun

VZ

Verizon

$47.36

0.66 (1.41%)

19:57
04/26/17
04/26
19:57
04/26/17
19:57
Periodicals
Verizon go90 boss departs, Business Insider says »

Verizon go90 chief Chip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

SSNLF

Samsung

19:45
04/26/17
04/26
19:45
04/26/17
19:45
Hot Stocks
Samsung sees FY17 earnings growth, cites health in memory, OLED »

"Moving on to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

19:42
04/26/17
04/26
19:42
04/26/17
19:42
Hot Stocks
Samsung sees Q2 growth due to 'robust' memory performance, Galaxy S8 launch »

"Looking ahead to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

19:40
04/26/17
04/26
19:40
04/26/17
19:40
Earnings
Samsung reports Q1 operating profit 9.9T won vs. 6.68T won last year »

Reports Q1 revenue 50.55T…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADM

Archer Daniels

$45.27

-0.31 (-0.68%)

19:36
04/26/17
04/26
19:36
04/26/17
19:36
Periodicals
Archer Daniels appoints new head of global trading desk, Reuters says »

Archer Daniels has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

FTI

TechnipFMC

$32.26

0.14 (0.44%)

19:35
04/26/17
04/26
19:35
04/26/17
19:35
Earnings
TechnipFMC reports Q1 adjusted EPS 71c, consensus 33c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

F

Ford

$11.60

0.12 (1.05%)

, GM

General Motors

$34.38

0.39 (1.15%)

19:29
04/26/17
04/26
19:29
04/26/17
19:29
Periodicals
Transportation, EPA chiefs to meet with major automakers, Reuters says »

Transportation Secretary…

F

Ford

$11.60

0.12 (1.05%)

GM

General Motors

$34.38

0.39 (1.15%)

TM

Toyota

$109.91

1.19 (1.09%)

VLKAY

Volkswagen

$32.13

-0.2 (-0.62%)

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

DDAIF

Daimler AG

$74.57

-0.6001 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 02

    May

CMCSA

Comcast

$38.79

0.3 (0.78%)

, CMCSK

Comcast

19:24
04/26/17
04/26
19:24
04/26/17
19:24
Hot Stocks
Comcast responds to FCC net neutrality news, says committed to open Internet »

Responding to FCC…

CMCSA

Comcast

$38.79

0.3 (0.78%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PCH

Potlatch

$46.50

1.25 (2.76%)

19:18
04/26/17
04/26
19:18
04/26/17
19:18
Earnings
Potlatch reports Q1 EPS 41c, consensus 20c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

DBOEY

Deutsche Boerse

$9.59

-0.005 (-0.05%)

19:13
04/26/17
04/26
19:13
04/26/17
19:13
Hot Stocks
Deutsche Boerse says plans EUR 200M repurchase program »

Deutsche Boerse announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$3.64

-0.11 (-2.93%)

19:03
04/26/17
04/26
19:03
04/26/17
19:03
Hot Stocks
Cleveland BioLabs names John Szydlo principal financial officer »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$30.62

-0.53 (-1.70%)

19:02
04/26/17
04/26
19:02
04/26/17
19:02
Hot Stocks
Suncor to repurchase up to C$2B of company's shares through NCIB »

Suncor announced plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

NBR

Nabors Industries

$11.74

-0.03 (-0.25%)

18:53
04/26/17
04/26
18:53
04/26/17
18:53
Earnings
Nabors Industries reports Q1 cont-op EPS with item (52c), consensus (35c) »

Reports Q1 revenue $563M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

RTN

Raytheon

$155.27

-0.74 (-0.47%)

18:40
04/26/17
04/26
18:40
04/26/17
18:40
Hot Stocks
Raytheon awarded $375M U.S. Air Force contract »

The U.S. Air Force…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

NOV

National Oilwell

$36.15

0.33 (0.92%)

18:38
04/26/17
04/26
18:38
04/26/17
18:38
Hot Stocks
National Oilwell reports Q1 book-to-bill of 41% for Rig Systems »

Backlog for capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 01

    May

OIS

Oil States

$32.10

-0.3 (-0.93%)

18:36
04/26/17
04/26
18:36
04/26/17
18:36
Earnings
Oil States reports Q1 adjusted EPS (34c), consensus (27c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

PSA

Public Storage

$223.93

-1.61 (-0.71%)

18:35
04/26/17
04/26
18:35
04/26/17
18:35
Earnings
Public Storage reports Q1 core FFO $2.37, consensus $1.65 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

NOV

National Oilwell

$36.15

0.33 (0.92%)

18:31
04/26/17
04/26
18:31
04/26/17
18:31
Earnings
National Oilwell reports Q1 adjusted EPS (17c), consensus (21c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 01

    May

PUB

People's Utah Bancorp

$27.55

-0.2 (-0.72%)

18:25
04/26/17
04/26
18:25
04/26/17
18:25
Hot Stocks
People's Utah Bancorp announces CEO succession in 2018 »

People's Utah…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

BSFT

BroadSoft

$38.70

0.45 (1.18%)

18:17
04/26/17
04/26
18:17
04/26/17
18:17
Hot Stocks
BroadSoft announces agreement with Telstra for Australia communications »

BroadSoft announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

RJF

Raymond James

$75.74

0.55 (0.73%)

18:14
04/26/17
04/26
18:14
04/26/17
18:14
Earnings
Raymond James reports Q2 adjusted EPS $1.28, consensus $1.14 »

Reports Q2 GAAP EPS 77c.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCTT

Ultra Clean

$17.51

-0.2 (-1.13%)

, TER

Teradyne

$33.77

0.21 (0.63%)

18:14
04/26/17
04/26
18:14
04/26/17
18:14
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ultra…

UCTT

Ultra Clean

$17.51

-0.2 (-1.13%)

TER

Teradyne

$33.77

0.21 (0.63%)

CRY

CryoLife

$16.75

0.5 (3.08%)

ALSN

Allison Transmission

$37.47

0.53 (1.43%)

MKSI

MKS Instruments

$75.35

0.95 (1.28%)

AXTI

AXT, Inc.

$6.15

-0.25 (-3.91%)

PYPL

PayPal

$44.41

-0.3 (-0.67%)

GGG

Graco

$99.80

1.45 (1.47%)

NOW

ServiceNow

$90.92

0.68 (0.75%)

XLNX

Xilinx

$59.99

-0.7 (-1.15%)

WPG

Washington Prime

$8.92

-0.09 (-1.00%)

MMLP

Martin Midstream Partners

$19.55

-0.15 (-0.76%)

CAVM

Cavium

$70.93

-0.31 (-0.44%)

WLL

Whiting Petroleum

$8.07

-0.22 (-2.65%)

ROG

Rogers Corporation

$92.47

3.23 (3.62%)

INTU

Intuit

$115.81

-3.27 (-2.75%)

WTW

Weight Watchers

$20.16

1.33 (7.06%)

HRB

H&R Block

$23.89

-0.35 (-1.44%)

MLNX

Mellanox

$50.90

-0.05 (-0.10%)

FFIV

F5 Networks

$137.30

-0.89 (-0.64%)

CMPR

Cimpress

$86.25

-0.07 (-0.08%)

CTXS

Citrix

$84.12

0.07 (0.08%)

NTGR

Netgear

$51.35

-1.55 (-2.93%)

ETH

Ethan Allen

$31.25

0.15 (0.48%)

AMGN

Amgen

$164.61

-0.09 (-0.05%)

KN

Knowles

$19.59

0.04 (0.20%)

BWLD

Buffalo Wild Wings

$162.40

-0.4 (-0.25%)

ORLY

O'Reilly Automotive

$265.07

1.11 (0.42%)

SAM

Boston Beer

$141.85

-2.45 (-1.70%)

AMSC

AMSC

$7.70

0.3 (4.05%)

SFST

Southern First Bancshares

$33.05

0.25 (0.76%)

BRKL

Brookline Bancorp

$15.95

0.35 (2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 16

    May

  • 17

    May

  • 30

    May

  • 31

    May

  • 07

    Jun

  • 12

    Jun

  • 15

    Jun

  • 20

    Jun

  • 21

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

  • 19

    Jul

  • 14

    Aug

  • 27

    Apr

  • 27

    Apr

NWE

NorthWestern

$59.92

-0.23 (-0.38%)

18:13
04/26/17
04/26
18:13
04/26/17
18:13
Earnings
Breaking Earnings news story on NorthWestern »

NorthWestern backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 21

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.